‘Is insulin right for me?’: Feasibility of a pilot randomised controlled trial and acceptability of a web‐based intervention to reduce psychological barriers to insulin therapy among adults with type 2 diabetes

Aims Acceptable and accessible interventions are needed to address ‘psychological insulin resistance’, which is a common barrier to insulin uptake among adults with type 2 diabetes (T2D). Our aim was to test the feasibility of a randomised controlled trial (RCT) study design and acceptability of a t...

Full description

Saved in:
Bibliographic Details
Published inDiabetic medicine Vol. 39; no. 3; pp. e14759 - n/a
Main Authors Holmes‐Truscott, Elizabeth, Holloway, Edith E., Husin, Hanafi M., Furler, John, Hagger, Virginia, Skinner, Timothy C., Speight, Jane
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aims Acceptable and accessible interventions are needed to address ‘psychological insulin resistance’, which is a common barrier to insulin uptake among adults with type 2 diabetes (T2D). Our aim was to test the feasibility of a randomised controlled trial (RCT) study design and acceptability of a theoretically grounded, psycho‐educational, web‐based resource to reduce negative insulin appraisals among adults with T2D. Methods A double‐blinded, parallel group, two‐arm pilot RCT (1:1), comparing intervention with active control (existing online information about insulin). Eligible participants were Australian adults with T2D, taking oral diabetes medications. Exclusion criteria: prior use of injectable medicines; being ‘very willing’ to commence insulin. Primary outcomes: study feasibility (recruitment ease, protocol fulfilment, attrition, data completeness); secondary outcomes: intervention acceptability (intervention engagement, user feedback) and likely efficacy (negative Insulin Treatment Appraisal Scale [ITAS] scores at follow‐up). Online surveys completed at baseline and 2 weeks. Results During 4‐week recruitment, 76 people expressed interest: 51 eligible and 35 enrolled (intervention = 17, control = 18; median[interquartile range] age = 62[53, 69] years; 17 women). Protocol fulfilment achieved by 26 (74%) participants (n = 13 per arm), with low participant attrition (n = 6, 17%). Intervention acceptability was high (>80% endorsement, except format preference = 60%). ITAS negative scores differed between‐groups at follow‐up (M diff = −6.5, 95% confidence interval: −10.7 to −2.4), favouring the intervention. Conclusions This novel web‐based resource (“Is insulin right for me?”) is acceptable and associated with a likely reduction in negative insulin appraisals, relative to existing resources. This pilot shows the study design is feasible and supports conduct of a fully powered RCT.
Bibliography:Funding information
Trial registration: ACTRN12619001382167
This investigator‐sponsored study is supported by funding from Sanofi‐Aventis Australia Pty Ltd (Sanofi). Sanofi was not involved in the design, collection, analysis, interpretation or reporting of the study but was given the opportunity to review the manuscript prior to submission. The decision to submit for publication was made independently by the authors. Sanofi will be allowed access to all de‐identified data from the study for research and audit purposes, if requested. Costs associated with participation incentives, website development and data management were funded (fully or partially) by the Australian Centre for Behavioural Research in Diabetes. In‐kind support including project oversight was provided by the Investigator team. EH‐T and JS are supported by the core funding to the Australian Centre for Behavioural Research in Diabetes provided by the collaboration between Diabetes Victoria and Deakin University. EH‐T is also supported by a Deakin University Deans Research Postdoctoral Fellowship.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0742-3071
1464-5491
DOI:10.1111/dme.14759